Summit Therapeutics Inc. - Common Stock (NQ:SMMT)

17.41 -0.07 (-0.43%)

Streaming Delayed Price Updated: 12:57 PM EST, Jan 2, 2026 Add to My Watchlist

Price and Volume

Volume	527,841
Open	17.75
Bid (Size)	17.40 (100)
Ask (Size)	17.43 (300)
Prev. Close	17.49
Today's Range	17.32 - 17.75
52wk Range	15.55 - 36.91
Shares Outstanding	97,381,774
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Biotech’s Resurgence: How a Year-End Rally and M&A Frenzy Set the Stage for 2026

December 31, 2025

As the final bells ring on Wall Street for 2025, the biotechnology sector is celebrating a dramatic reversal of fortune. After years of navigating high interest rates and regulatory uncertainty, the...

Via MarketMinute

Up Nearly 400% This Year, Can Oklo Stock Still Rise Higher? ↗

December 10, 2025

Many investors see this nuclear power company as a possible answer to the growing energy needs from artificial intelligence, and it has benefited from that.

Via The Motley Fool

Performance

YTD	N/A	N/A
1 Month	+1.0%	+1.0%
3 Month	-16.6%	-16.6%
6 Month	-29.1%	-29.1%
1 Year	-5.1%	-5.1%

More News

2 Stocks Up Over 600% in the Past 3 Years With More Room to Run ↗

December 09, 2025

Via The Motley Fool

Summit Therapeutics Stock Sparks Retail Buzz After Ivonescimab Combo Cuts Cancer Progression Risk By 40% ↗

October 19, 2025

Via Stocktwits

An Overview of Summit Therapeutics's Earnings ↗

October 17, 2025

Via Benzinga

Beyond AI: How Non-AI Tech Innovations are Fueling a New Era of Stock Market Growth

December 11, 2025

Via MarketMinute

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

December 05, 2025

From Summit Therapeutics

Via Business Wire

Trading Near Its 52-Week Low, Is Summit Therapeutics a Good Stock to Buy Right Now? ↗

December 05, 2025

Via The Motley Fool

Don't Buy Summit Therapeutics Until This Big Thing Happen ↗

December 03, 2025

Via The Motley Fool

2 Monster Stocks in the Making to Buy and Hold ↗

December 02, 2025

Via The Motley Fool

Summit SMMT Q3 2025 Earnings Call Transcript ↗

November 27, 2025

Via The Motley Fool

Ivonescimab Plus Chemotherapy Demonstrates a Statistically Significant Benefit in Overall Survival with a Hazard Ratio of 0.74 in 2L+ Treatment of Patients with EGFRm NSCLC in HARMONi-A Study Conducted by Akeso in China

November 07, 2025

From Summit Therapeutics

Via Business Wire

Summit Therapeutics to Present at Upcoming Investor Conferences

November 04, 2025

From Summit Therapeutics

Via Business Wire

Overall Survival Data from HARMONi-A, Featuring Ivonescimab in Combination with Chemotherapy vs. Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC in China, to be Showcased at SITC 2025

October 31, 2025

From Summit Therapeutics

Via Business Wire

Alpha Buying: When Insiders Buy Big & Why It Works in Every Market ↗

October 30, 2025

Via Benzinga

Why Wall Street Is Backing These 3 Comeback Stocks ↗

October 28, 2025

Via MarketBeat

1 Monster Stock in the Making to Buy and Hold ↗

October 27, 2025

Via The Motley Fool

Summit Therapeutics: A Risky Bet in the Biotech Arena? ↗

October 24, 2025

Via The Motley Fool

Summit Therapeutics Raises $500 Million in Private Placement

October 22, 2025

From Summit Therapeutics

Via Business Wire

What's Going On With Summit Therapeutics Stock On Monday? ↗

October 20, 2025

Via Benzinga

Retail Investors' Top Stocks With Earnings This Week: Tesla, Netflix, Intel and More ↗

October 20, 2025

Via Benzinga

Summit Therapeutics Inc (NASDAQ:SMMT) Reports Wider-Than-Expected Q3 2025 Loss ↗

October 20, 2025

Via Chartmill

Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2025

October 20, 2025

From Summit Therapeutics

Via Business Wire

Earnings Scheduled For October 20, 2025 ↗

October 20, 2025

Via Benzinga

Ivonescimab with Chemotherapy Reduced the Risk of Disease Progression or Death by 40% Compared to Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China

October 19, 2025

From Summit Therapeutics

Via Business Wire

Frequently Asked Questions

Is Summit Therapeutics Inc. - Common Stock publicly traded?

Yes, Summit Therapeutics Inc. - Common Stock is publicly traded.

What exchange does Summit Therapeutics Inc. - Common Stock trade on?

Summit Therapeutics Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Summit Therapeutics Inc. - Common Stock?

The ticker symbol for Summit Therapeutics Inc. - Common Stock is SMMT on the Nasdaq Stock Market

What is the current price of Summit Therapeutics Inc. - Common Stock?

The current price of Summit Therapeutics Inc. - Common Stock is 17.41

When was Summit Therapeutics Inc. - Common Stock last traded?

The last trade of Summit Therapeutics Inc. - Common Stock was at 01/02/26 12:57 PM ET

What is the market capitalization of Summit Therapeutics Inc. - Common Stock?

The market capitalization of Summit Therapeutics Inc. - Common Stock is 1.70B

How many shares of Summit Therapeutics Inc. - Common Stock are outstanding?

Summit Therapeutics Inc. - Common Stock has 2B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.